Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gossamer Bio Inc (NQ: GOSS )

7.490 +0.040 (+0.54%)
Streaming Delayed Price Updated: 9:30 AM EDT, May 26, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,583
Open 7.490
Bid (Size) 7.230 (10)
Ask (Size) 7.890 (1)
Prev. Close 7.450
Today's Range 7.490 - 7.490
52wk Range 6.275 - 14.30
Shares Outstanding 75,993,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Gossamer Bio Announces First Quarter 2022 Financial Results and Provides Business Update
From Gossamer Bio, Inc.
Via Business Wire
71 Biggest Movers From Yesterday
Gainers Evoke Pharma, Inc. (NASDAQ: EVOK) shares jumped 118.5% to close at $0.86 on Tuesday. The FDA granted new drug product exclusivity to Evoke Pharma's Gimoti (... 
Via Benzinga

Performance

YTD
-37.01%
-37.01%
1 Month
-17.51%
-17.51%
3 Month
-17.24%
-17.24%
6 Month
-33.42%
-33.42%
1 Year
-16.31%
-16.31%

More News

Read More
Where Gossamer Bio Stands With Analysts
Via Benzinga
Gossamer Bio Pulls Plug On Mid-Stage Ulcerative Colitis Program
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Gossamer Bio Announces GB004 Topline Results from Phase 2 SHIFT-UC Study in Ulcerative Colitis and Provides Corporate Update
From Gossamer Bio, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2022
Via Benzinga
Recap: Gossamer Bio Q4 Earnings
Via Benzinga
Gossamer Bio Earnings Preview
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022
Via Benzinga
Earnings Scheduled For March 3, 2022
Via Benzinga
Gossamer Bio to Announce Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 3, 2022
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Third Quarter 2021 Financial Results and Provides Corporate Update
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio Announces Addition of Two CNS-Penetrant BTK Inhibitors to its Product Candidate Pipeline: GB5121 & GB7208
From Gossamer Bio, Inc.
Via Business Wire
Gossamer Bio to Host Webcast Announcing its Next Clinical Product Candidates on October 11, 2021
From Gossamer Bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
Via Benzinga
31 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
50 Biggest Movers From Yesterday
Via Benzinga
Gossamer Bio Announces Appointment of Bryan Giraudo as Chief Operating Officer, in addition to Chief Financial Officer Role
From Gossamer Bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Gossamer Bio Announces Second Quarter 2021 Financial Results and Provides Corporate Update
From Gossamer Bio, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.